Shi Han Wei

Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals.

Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection.

Beijing Amcare Medical Management Co., Ltd. engages in the sale of medical devices and provision of medical services. Its business activities include medical management consulting, medical technology development, technology consulting, and sale of daily necessities, packaging materials, chemical products, and building materials. The company was founded on October 22, 2012 and is headquartered in Beijing, China.